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Langerhans cell (LCH) histiocytosis occurs in 1 per 560,000 adults with variable manifestations. However,
it rarely presents with simultaneous and multiple endocrine dysfunctions early in the course of the
disease. We report a case of LCH in an adult manifesting with adipsic diabetes insipidus, diabetes mellitus
and hypopituitarism.
A 41-year-old Filipino male presented with polyuria and polydipsia. He was initially diagnosed as a
simple case of diabetes mellitus but symptoms did not fully resolve after control of glucose. He had loss
of thirst perception, erectile dysfunction and memory impairment. These were followed by crusting skin
lesions over the face, trunk and extremities. He was hospitalized because of altered mentation because of
severe dehydration, hypernatremia and hyperglycemia. Subsequent work-up showed thickened hypo-
thalamus and infundibulum on magnetic resonance imaging. Skin biopsy and immunostaining with
S-100 and CD1a conﬁrmed the diagnosis. There was partial improvement after chemotherapy. He was
maintained on desmopressin and testosterone.
Multiple endocrinopathies can be the presenting signs of adult-onset LCH. They can be harbinger of
subsequent involvement of other organs. Central diabetes insipidus, other hypothalamic dysfunctions
and anterior pituitary hormonal deﬁciencies, when present at the onset as in this case, will likely have
poor response to treatment despite improvement of other non-endocrine organs. The permanent lesions
in the hypothalamus and pituitary gland warrants continued endocrine evaluation and intervention.
 2016 The Authors. Published by Elsevier Inc. This is an open access article under the CC BY-NC-ND
license (http://creativecommons.org/licenses/by-nc-nd/4.0/).Introduction
Langerhans cell histiocytosis (LCH) is characterized by prolifer-
ation of differentiated cells of the monocyte-macrophage series
called histiocytes. It was historically termed as Histiocytosis X and
thought to be a reactive disease. Recent data indicate that there
could also be an underlying neoplastic mechanism as demonstrated
by familial clustering, chromosomal instability and oncogenic BRAF
V600Emutation in 57% of cases [1]. It is estimated that 1 case of LCH
occurs per 560,000 adult [2,3]. Because the true prevalence and
incidence of the disease is low, our current knowledge of its clinical
course is mostly based on retrospective data gathered over many
years.smendoza24@yahoo.com.ph
Inc. This is an open access article uThe new disease classiﬁcation has been simpliﬁed to single
system LCH and multisystem LCH [3]. Multisystem LCH, as seen in
45% of cases, involves 2 or more organs or systems (lung, bone, skin,
endocrine and central nervous systems, liver, spleen, lymph nodes
and marrow). LCH has a particular predilection for involvement of
the hypothalamo-pituitary axis. In a retrospective study by Kaltsas
et al. in 2000, he followed 12 adult LCH. DI and anterior pituitary
dysfunctionwere present in 4 and 3 patients respectively but only 1
had both at the onset. None in our literature search and adult pa-
tient with LCH presented with both hypothalamus and pituitary
dysfunction complicated by adipsia and diabetes mellitus [4].
We report a case of an adult Filipino male diagnosed with LCH
and with multiple endocrinopathies, each complicating the other.
The central diabetes insipidus was initially masked by diabetes
mellitus. Furthermore, the patient was pushed to dehydration by
loss of thirst sensation or adipsia. On review of history, he already
had manifestation of hypogonadism at the onset of disease. These
endocrine dysfunctions heralded other systemic manifestations ofnder the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
Figure 1. Graphical representation of daily blood glucose levels (red), serum sodium
(blue) and urine volume (green). Despite adequate hydration and correction of hy-
perglycemia, only the introduction of desmopressin had signiﬁcantly improved serum
sodium and urine volume.
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association of these hormonal disorders, the course of the disease
and the response to treatment.Case report
A 42-year-old Filipino displayed 6-month history of worsening
polyuria.Hewas investigated fordiabetesmellitus. The fastingplasma
glucose (8.5mmol/L)andglycosylatedhemoglobin (HbA1C,11%)were
elevatedhencehewasstartedon insulin andmetformin.Glycosylated
hemoglobin improved after 3 months to 7.2% however there was still
polyuria. Five months later, he noted eruptions of multiple purpuric
and pruritic rashes over the trunk and premature loss of teeth. The
symptoms were later accompanied by cognitive dysfunction,
emotional labilityandataxia. Therewerealso fatigueand lossof libido.
Despite persistent polyuria, there was progressive deterioration of
thirst perception. He was admitted because of altered mentation
secondary to severe dehydration with hypotension (80/50 mm Hg),Figure 2. Multiple purpuric rashestachycardia (138 beats per minute) and azotemia (serum creatinine
194 mmol/L and BUN 84 mmol/L). He had hyperosmolar hyper-
natremia (serum osmolality 360 mOsm/kg/H2O; serum sodium
181 mmol/L; plasma glucose 20.2 mmol/L). Despite adequate hydra-
tion, there was persistent of hypernatremia and hypoosmolal urine.
These and the signiﬁcant response to desmopressin as depicted in
Figure 1 were compatible with complete central DI.
On physical examinationwas donewhen hewas more stable. He
was overweight (body mass index 23.6 kg/m2, Asia-Paciﬁc Guide-
lines). There were multiple pruritic erythematous to purpuric
macules and papules with erosions and crusting over the scalp, face
and chest. Therewere also gingival swelling and teethmalocclusion
(Figures 2 and 3). He had pallor and gynecomastia. He had no focal
motor deﬁcit however he had an ataxic gait.
A cranial magnetic resonance imaging (MRI) on Figure 4 showed
thickened hypothalami and pituitary infundibulum. There was also
a 6 millimeter pontine lesion. The posterior bright spot was absent.
Hormonal tests (shown in Table 1) were consistent with secondary
hypogonadism. There was an indirect evidence of growth hormone
deﬁciency. The levels of fasting insulin (35 uIU/mL) and C-peptide
(7.33 ngmL) were elevated. The blood is drawn fasting at 8 in the
morningwhile the patient was off insulin for 5 days. Antibody panel
and pancreatic biopsy were not performed. Additional ﬁnding were
pancytopenia on peripheral blood smear, maxillary-mandibular
osteolysis on radiograph and multiple hepatic nodules on
computed tomography. Bone marrow biopsy disclosed only
moderately hypocellular marrow and erythroid hyperplasia. There
were no malignant cells found in the liver biopsy. Punch biopsy of
the skin lesions was suggestive of Langerhans cell histiocytosis.
Immunostaining for S-100 and CD1a antigens were conﬁrmatory of
the diagnosis (Figure 5).
The patient was discharged on desmopressin 0.1 mg twice daily
with instruction to drink ﬁxed amount of ﬂuid to avoid wide so-
dium ﬂuctuations. He was started on testosterone replacement. He
received chemotherapy with vinblastine and prednisone for
6months. Therewas a signiﬁcant resolution of skin and gum lesions
(Figure 6) and there was improvement in memory, gait and overall
function. A repeat cranial MRI demonstrated no difference from
pre-treatment ﬁndings, consistent with the refractory status of the
DI and anterior pituitary hormone deﬁciencies. He was still main-
tained on insulin for the diabetes mellitus.over the scalp, face and chest.
Figure 3. Gingival swelling (left) and accelerated loss of teeth with osteolytic lesions of the alveolar bone on radiograph (right).
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Endocrinologists should consider LCH in an adult patient pre-
senting with DI and anterior pituitary hormone deﬁciency on the
background of sellar or parasellar lesions. MRI would show loss of
pituitary bright spot, thickened infundibulum and hypothalamic
enhancement as noted in this patient. Other neoplastic, inﬂam-
matory or infectious and inﬁltrative diseases need to be ruled out.
In a registry report of 274 adults with biopsy-proven adult LCH,
there was a slight male preponderance (52.2%) and the mean age at
the onset of diagnosis was 33  14 years; 68.6% had multisystem
disease and 29.6% had diabetes insipidus [2].Figure 4. Cranial MRI showing thickened pituitary infundibulum (upper left panel); contras
panel); and a 6-mm pontine lesion (lower right panel).Central DI can develop either before, simultaneous with or
subsequent to a diagnosis of LCH based from the presence of other
lesions. Among pediatric patients, multisystem disease and
craniofacial involvement at diagnosis carry a signiﬁcantly increased
risk to develop DI during their course [5]. On the other hand, DI can
be the presenting feature in about 1/3 of patients [4]. It has been
reported that pituitary stalk thickening precedes peripheral lesions
by several months. During this early phase of the disease, a water
deprivation test and possibly pituitary stalk biopsy may be helpful.
In 2 studies evaluating the efﬁcacy of chemotherapy among chil-
dren with LCH, pre-existing central DI were neither reversed nor




Serum TSH 1.5 uIU/mL 0.4e4.5
Serum free T4 1.6 ng/dL 0.8e1.8
Serum cortisol 17.8 mcg/dL 5e25
Serum FSH 2.82 mIU/mL 1e8
Serum LH 2.38 mIU/mL 1.14e8.75
Serum testosterone 0.84 ng/mL 1.95e11.38
Serum prolactin 8.6 ng/mL 4e23
Serum IGF-1 62 ng/mL 121e237
Plasma glucose 6.8 mmol/L 3.6e5.6
Plasma insulin 35.0 uU/mL 5e10
Plasma C-peptide 7.33 ng/mL 0.78e5.19
a The blood is drawn fasting at 8 in themorning. The plasma insulin and C-peptide
was taken while the patient is off insulin for 5 days.
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discontinuation of desmopressin and disappearance of pituitary
stalk thickening [6,7]. There is one case report of successful treat-
ment after chemotherapy with vinblastine, prednisolone and 6-
mercaptopurine [8]. However, most central DI in adult multisystem
LCH were advanced at the time of therapy. Adipsic hypernatremia
was reported after surgical clipping of aneurysm or escision of large
craniopharyngioma and macroadenoma [9]. There was one report
of adipsic diabetes insipidus in LCH. The probable mechanism
behind adipsic hypernatremia in LCH could be inﬁltration of thirst
center osmoreceptors in the hypothalamus. In a retrospective re-
view of 12 patients with LCH and DI by Kaltsas et al., 8 eventually
developed anterior pituitary hormone deﬁciencies at a median of
4.5 years (range 2e22). In the same study, the most common and
earliest hormone deﬁciency was growth hormone (median 2 years,
range 2e22) followed by FSH-LH (median 7 years, range 2e22). TSH
and ACTH deﬁciencies were noted after a median of 10 years.Figure 5. Skin punch biopsy showing characteristic LC inﬁltrates with reniform nuclei and
panel) and CD1a (lower right panel).Prolactin elevation, if present, is attributable to hypothalamic
infundibular inﬁltration wherein there is impaired release of
inhibitory dopamine.
Nonendocrine hypothalamic dysfunctions like adipsia and
memory impairment may follow. It is usually seen at a median of 10
years [4]. The lack of thirst perception and noncompliance due to
memory disturbancewould have signiﬁcant impact among patients
with LCH and DI. Weight, sleep and thermoregulatory disorders are
also possible. The varying presentation and their timing of mani-
festation reﬂect the heterogenous nature of the disease. The
structural changes in the in the hypothalamic-pituitary axis often
heralds involvement of the other parts of the central nervous sys-
tem and its attendant neurologic sequelae which probably reﬂects
the progressive and permanent nature of this inﬁltrative disease.
Effective measures that can prevent or reverse neuroendocrine
deterioration remain to be deﬁned.
It is very interesting to knowwhether diabetesmellitus is part of
histiocyte inﬁltration of pancreatic b-cells or a result of obesity and
insulin resistance secondary hypothalamic involvement. In an
observational study by Alexandraki et al., 4 out of 14 patients
with LCH had abnormal glucose metabolism (3 impaired glucose
tolerance and 1 diabetes mellitus).This abnormality in glucose
metabolism, observed only in active disease, was attributed to pro-
inﬂammatory state [10]. To date, only one study reported pancreatic
inﬁltration but this was a child and not associated with diabetes
mellitus [11]. In the case presented, the clinical features and
biochemical tests favored type 2 DM (overweight and insulin
resistance). Autoimmune panel may help but only pancreatic bi-
opsy can give the deﬁnitive diagnosis.
The treatment of multisystem LCH conventionally follows those
of pediatric cases. A combination of vinblastine and prednisone is
given in the initial (6 weeks) and maintenance (12 months) phase
[12]. Lack of response after 6months of treatment is associatedwith
treatment failure and high (66%) mortality [13].nuclear groove (H&E, upper panel) and positive immunostaining for S100 (lower left
Figure 6. Improvement of skin and gum lesions 6 months after the patient received his initial dose of vinblastine and prednisone chemotherapy.
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drug for multisystem LCH with lung or bone lesion [14,15].
Vemurafenib, a novel tyrosine kinase inhibitor, is a targeted therapy
for refractory LCH [16]. The mainstay of treatment in adipsic DI
associated with LCH is desmopressin, a synthetic long-acting
vasopressin analog, together with ﬁxed ﬂuid intake. Testosterone
is beneﬁcial for symptoms of hypogonadism as well as anemia.
Growth hormone deﬁciency in adults needs to be addressed.
Anticipation of secondary hypothyroidism and adrenal insufﬁ-
ciency is part of the disease monitoring.Conclusion
To the best of our knowledge, this is the ﬁrst case of adult-onset
Langerhans cell histiocytosis presenting simultaneously with mul-
tiple endocrinopathies at the onset of the disease. In this case, the
presence of complete central DI with adipsia and hypopituitarism
in conjunction with structural abnormalities seen in MRI at diag-
nosis portends poor response of these endocrine organs to
chemotherapy. Diabetes mellitus may complicate the early diag-
nosis of central DI which is said to have better prognosis when
diagnosed earlier. The onset of anterior pituitary hormone de-
ﬁciencies cannot be predicted in LCH. Hence, regular endocrine
monitoring should be implemented.Consent
Written informed consent was obtained from the patient for
publication of this case report and accompanying images.Conﬂict of interest
The authors declare they have no conﬂicts of interest.References
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